Skip to content
Research Article Open access CC BY 3.0

The Safety and Effectiveness of Single and Repeat Dosing of Intra-Articular Anti-Tumour Necrosis Factor Treatment after Failure of Intra-Articular Steroids

Justin Chia, Janet Pope

Journal of Advances in Medicine and Medical Research · pp. 39–53 · Published 6 Dec 2011

10.9734/BJMMR/2012/805

Abstract

Objectives: To determine if intra-articular (ia) anti-tumour necrosis factor (TNF) yielded benefit in patients failing ia steroid injections and determine the safety and durability of single and repeated ia anti-TNF treatment in inflammatory arthritis. Methods: Patients with inflammatory arthritis having one or two active joints, and having failed previous ia steroids were injected with ia adalimumab or ia etanercept mixed with triamcinolone and lidocaine via a retrospective chart audit. Results: Twenty-six patients were followed: 18 received ia adalimumab, 12 received ia etanercept and 4 received both. Twenty-five knees, 17 ankles, 1 wrist and 1 PIP were injected of whom 6 had repeated injections to a joint. Nine were on concomitant systemic anti-TNF therapy. Fifteen had RA, 4 had a seronegativearthropathy, 3 had psoriatic arthritis, and 4 had other arthritis. When determining a response to ia anti-TNF for > 2 months in patients with sufficient follow up 13 of 18 receiving iaadalimumab and 6/7 with ia etanercept had benefit. There were no serious adverse events (SAEs) and only one AE in a wrist post ia adalimumab, with rebound inflammation after 6 weeks of marked relief. Two were able to cancel or postpone joint surgery(knee and ankle)and one cancelled an yttrium injection. Conclusions: There were no SAEs and prolonged benefit was found with ia anti-TNF and steroids and lidocaine compared to previous ia steroids with lidocaine in the majority (20/27). Although not approved for ia administration, ia anti-TNFs may be cost effective in persistent synovitis of one or two joints recalcitrant to ia steroids.

Inta-articular injection anti-tumour necrosis factor inflammatory arthritis

References (23)

  1. 1 Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies [DOI]
  2. 2 Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis [DOI]
  3. 3 Intra‐articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders [DOI]
  4. 4 The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
  5. 5 Adalimumab: a review of side effects [DOI]
  6. 6 Intra-articular drug delivery systems for the treatment of rheumatic diseases: A review of the factors influencing their performance [DOI]
  7. 7 Safety, Tolerability, and Clinical Outcomes after Intraarticular Injection of a Recombinant Adeno-associated Vector Containing a Tumor Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study [DOI]
  8. 8 Treatment of rheumatoid arthritis [DOI]
  9. 9 Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: A role for scintigraphy with 99mTc‐infliximab [DOI]
  10. 10 A randomized, controlled study of a single intra‐articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis [DOI]
  11. 11 Successful treatment with multiple intra‐articular injections of infliximab in a patient with psoriatic arthritis [DOI]
  12. 12 Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study [DOI]
  13. 13 Local infusion of infliximab for the treatment of acute joint inflammation [DOI]
  14. 14 Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
  15. 15 Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor α [DOI]
  16. 16 Safety of intra-articular injection of etanercept in small-joint arthritis: an uncontrolled, pilot-study with independent imaging assessment [DOI]
  17. 17 Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis [DOI]
  18. 18 Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee-joints of patients with rheumatoid arthritis [DOI]
  19. 19 Chronic sarcoid arthritis treated with intraarticular etanercept [DOI]
  20. 20 Acute injection site reaction to intraarticular etanercept administration [DOI]
  21. 21 Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy [DOI]
  22. 22 Intra-articular therapy with infliximab in psoriatic arthritis: efficacy and safety in refractory monoarthritis [DOI]
  23. 23 Intraarticular injection of anti–tumor necrosis factor: Comment on the letter by Arnold et al [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

24

Page views

0

PDF downloads

24

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.